• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

    11/13/24 4:30:24 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANIP alert in real time by email
    SC 13G/A 1 tm2427812d2_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     
      ANI Pharmaceuticals, Inc.  
    (Name of Issuer)
     
      Common Stock, $0.0001 par value  
    (Title of Class of Securities)
     
      00182C103  
    (CUSIP Number)
     
      September 30, 2024  
    (Date of event which requires filing of this statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x   Rule 13d-1(b)
    ¨   Rule 13d-1(c)
    ¨   Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

     

    CUSIP No. 00182C103

     

    13G/A Page 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    56,671 shares of Common Stock

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    56,671 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    56,671 shares of Common Stock

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.27%

     

    12

    TYPE OF REPORTING PERSON

    PN, IA

     

           

     

     

     

    CUSIP No. 00182C103

     

    13G/A Page 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    56,671 shares of Common Stock

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    56,671 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    56,671 shares of Common Stock

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.27%

     

    12

    TYPE OF REPORTING PERSON

    IN

     

           

     

     

     

    CUSIP No. 00182C103

     

    13G/A Page 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is ANI Pharmaceuticals, Inc. (the “Issuer”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer’s principal executive offices are located at 210 Main Street West, Baudette, MN, 56623.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP (“Rubric Capital”), the investment adviser to certain investment funds and/or accounts (collectively, the “Rubric Funds”) that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen (“Mr. Rosen”), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

     

    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, $0.0001 par value (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER:
       
      00182C103

     

     

     

     

    CUSIP No. 00182C103

     

    13G/A Page 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
           
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
           
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
           
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
           
      (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
           
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 21,030,069 shares of Common Stock outstanding as of July 30, 2024, as reported in the Issuer’s Quarterly on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 6, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.

     

     

     

     

     

    CUSIP No. 00182C103

     

    13G/A Page 6 of 7 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

    CUSIP No. 00182C103

     

    13G/A Page 7 of 7 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: November 13, 2024

     

    RUBRIC CAPITAL MANAGEMENT LP

     

     

     
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  

     

     

    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

     

    Get the next $ANIP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIP

    DatePrice TargetRatingAnalyst
    7/10/2025$84.00Buy
    H.C. Wainwright
    3/14/2025$80.00Buy
    Jefferies
    3/12/2025$85.00Overweight
    Analyst
    12/11/2024$80.00Outperform
    Leerink Partners
    10/11/2024$68.00Overweight
    Piper Sandler
    3/15/2024$80.00Overweight
    CapitalOne
    8/22/2023$60.00 → $73.00Buy
    H.C. Wainwright
    3/1/2023$55.00Buy
    Guggenheim
    More analyst ratings

    $ANIP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

    Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of $104.0 million, which includes: Purified Cortrophin® Gel net revenues of $81.6 million, an increase of 66.0% year-over-year, andILUVIEN® and YUTIQ® net revenues of $22.3 million Generics quarterly net revenues of $90.3 million, an increase of 22.1% year-over-year Delivered record quarterly adjusted non-GAAP EBITDA of $54.1 million, an increase of 62.8% year-over-yearDiluted GAAP income per share of $0.36 and record adjusted non-GAAP diluted earnings per share of $1.80Increased 2025 guidance

    8/8/25 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

    PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will host a conference call to discuss the results as follows: DateFriday, August 8, 2025  Time8:30 a.m. ET  Toll free (U.S.)800-343-4136  Conference ID5034065  Webcast (live and replay)www.anipharmaceuticals.com, under

    8/1/25 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

    IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a jury in the Superior Court of the State of Delaware (the "Court") unanimously found in favor of CG Oncology on all claims in a March 2024 lawsuit brought by ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI"). The jury unanimously rejected all of ANI Pharmaceuticals' claims for unjust enrichment damages after Judge Sheldon K. Rennie, on July 16, 2025, had ruled in favor of CG Oncology that, as a matter of law, ANI Pharm

    7/29/25 4:05:00 PM ET
    $ANIP
    $CGON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leonard Matthew J sold $611,635 worth of shares (6,937 units at $88.17), decreasing direct ownership by 42% to 9,392 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    8/18/25 5:23:59 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walsh Patrick D sold $801,450 worth of shares (9,000 units at $89.05), decreasing direct ownership by 11% to 70,048 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    8/18/25 4:34:32 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HEAD OF R&D, COO-NOVITIUM OPS Shanmugam Muthusamy sold $8,824,533 worth of shares (100,000 units at $88.25) (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    8/18/25 4:32:05 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ANIP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    H.C. Wainwright initiated coverage on ANI Pharma with a new price target

    H.C. Wainwright initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $84.00

    7/10/25 8:50:19 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on ANI Pharma with a new price target

    Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00

    3/14/25 7:26:09 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on ANI Pharma with a new price target

    Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00

    3/12/25 7:20:36 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

    Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

    3/8/21 5:11:24 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXYCODONE AND ASPIRIN

    Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

    3/8/21 5:11:06 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for EZETIMIBE AND SIMVASTATIN

    Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

    2/25/21 5:09:42 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    SEC Filings

    View All

    SEC Form 10-Q filed by ANI Pharmaceuticals Inc.

    10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    8/8/25 7:01:33 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    8/8/25 6:56:43 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    7/29/25 4:55:48 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Leadership Updates

    Live Leadership Updates

    View All

    Alcami Announces CEO Transition

    Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

    1/13/25 11:12:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

    -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi

    8/23/23 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

    ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for

    9/12/22 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

    SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    11/13/24 4:30:24 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

    SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    3/14/24 7:30:38 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ANI Pharmaceuticals Inc.

    SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    2/13/24 4:58:56 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Financials

    Live finance-specific insights

    View All

    ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

    Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of $104.0 million, which includes: Purified Cortrophin® Gel net revenues of $81.6 million, an increase of 66.0% year-over-year, andILUVIEN® and YUTIQ® net revenues of $22.3 million Generics quarterly net revenues of $90.3 million, an increase of 22.1% year-over-year Delivered record quarterly adjusted non-GAAP EBITDA of $54.1 million, an increase of 62.8% year-over-yearDiluted GAAP income per share of $0.36 and record adjusted non-GAAP diluted earnings per share of $1.80Increased 2025 guidance

    8/8/25 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

    PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will host a conference call to discuss the results as follows: DateFriday, August 8, 2025  Time8:30 a.m. ET  Toll free (U.S.)800-343-4136  Conference ID5034065  Webcast (live and replay)www.anipharmaceuticals.com, under

    8/1/25 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

    Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singer, M.D. in a paper-on-demand presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Conference call scheduled for today at 8:30 am ET PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macula

    7/23/25 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care